Two novel human antitumor immunoconjugates, engineered by fusion of a single-chain antibody fragment against human ErbB2 receptor, termed Erbicin, with either a human RNase or the Fc region of a human IgG1 , are selectively cytotoxic for ErbB2-positive cancer cellsin vitro andin vivo.